What is GTBP's P/E ratio?

GT Biopharma Inc (GTBP) currently trades at a P/E ratio of 1.42.

GT Biopharma Inc reports a Return on Equity (ROE) of -629.74%.

What is GTBP's dividend yield?

GT Biopharma Inc offers a dividend yield of 0.00%.

What is GTBP's Quality Score?

Our AI rates GTBP's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy GTBP?

Our AI Timing Score for GTBP is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does GTBP belong to?

GT Biopharma Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

GT Biopharma Inc (GTBP) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-03-31)

GTBP AI Analysis Summary

Our AI summary for GTBP: GT Biopharma Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 1.42, ROE of -629.74%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

GTBP

GT Biopharma Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 87

USD 0.32

-0.01 (-2.64%) Day Change

Watchlist Portfolio Compare Chart

1.42

P/E

0.32

D/E

-629.7%

ROE

-477.5%

ROA

0.00%

Div Yield

0.01

PEG

GT BIOPHARMA INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 0.32 Price -0.01 (-2.64%) Day Change	NEWS SCORE: 87

GTBP, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...

Loading chart...

15 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

50%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	87
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	0.32
PBV / Sector	1.55 / 44,105.10 GOOD
Earning Per Share	-1.29

PE / Sector	1.42 / 19.37 GREAT
PEG or PE/Growth / Sector	0.01 / 1.06 GREAT
Average 1M Daily Value	0.25 M GREAT
Average 1W Daily Value	0.13 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 97.23
NPM Average (%) / Sector	N/A / -1,697.84
NPM Change Average (%) / Sector	N/A / 5,097.59
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-477.53 / 185,260.64
ROA Average (%) / Sector	-263.39 / 36,684.64
ROA Change Average (%) / Sector	117.44 / 422,221.42 GREAT
ROE (%) / Sector	-629.74 / 243,761.81
ROE Average (%) / Sector	-122.23 / 48,758.38
ROE Change Average (%) / Sector	-263.03 / 424,967.86
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

Registration Details

Analyze Date	2026-08-06 08:00:05
Symbol	GTBP
Name	GT BIOPHARMA INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	36.06 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	11.76 / 9,702.21

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 315 Montgomery Street, San Francisco, CA, United States, 94104

Phone: 415 919 4040

Website: https://www.gtbiopharma.com

Sector: Healthcare >> Biotechnology

Description: GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.